• Something wrong with this record ?

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

L. Kandolf Sekulovic, K. Peris, A. Hauschild, A. Stratigos, JJ. Grob, P. Nathan, R. Dummer, AM. Forsea, C. Hoeller, H. Gogas, L. Demidov, C. Lebbe, C. Blank, J. Olah, L. Bastholt, D. Herceg, B. Neyns, R. Vieira, J. Hansson, P. Rutkowski, I....

. 2017 ; 75 (-) : 313-322. [pub] 20170304

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17030986

BACKGROUND: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). MATERIALS AND METHODS: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. RESULTS: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. CONCLUSIONS: Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry.

APHP Hospital Saint Louis Paris France

Carol Davila University of Medicine and Pharmacy Elias University Hospital Bucharest Romania

Centre for Dermatooncology Department of Dermatology Eberhard Karls University Tuebingen Germany

Clinic for Oncology and Radiotherapy Podgorica Montenegro

Clinic of Oncodermatology National Cancer Center Sofia Bulgaria

Department of Clinical Oncology Hospital Universitario Virgen Macarena Sevilla Spain

Department of Dermatology and Allergology University of Szeged Hungary

Department of Dermatology and Venerology and Allergy Medical University Innsbruck Austria

Department of Dermatology Medical Faculty Military Medical Academy Belgrade Serbia

Department of Dermatology Medical Faculty University of Coimbra Portugal

Department of Dermatology Medical University of Vienna Vienna Austria

Department of Dermatology University Hospital Schleswig Holstein Campus Kiel Kiel Germany

Department of Dermatology Vilnius University Lithuania

Department of Medical Oncology Universitair Ziekenhuis Brussel Vrije Universiteit Brussel Brussels Belgium

Department of Oncology Odense University Hospital Denmark

Department of Oncology Pathology Karolinska Institutet and Karolinska University Hospital Solna Stockholm Sweden

Department of Oncology University Hospital Sarajevo Bosnia and Herzegovina

Department of Oncology University Hospital Zagreb Croatia

Division of Dermatology and Venerology Medical University of Graz Graz Austria

General Teaching Hospital Prague Czech Republic

Institute of Dermatology Catholic University of the Sacred Heart Rome Italy

Institute of Oncology and Radiology of Serbia Belgrade Serbia

Institute of Oncology Ljubljana Ljubljana Slovenia

Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology Warszawa Poland

Mount Vernon Cancer Centre Northwood United Kingdom

N N Alexandrov National Cancer Сenter of Belarus Minsk Belarus

National and Kapodistrian University of Athens Greece

National Cancer Institute Kiev Ukraine

Netherland Cancer Institute Amsterdam Netherlands

NN Blokhin Russian Cancer Research Center Moscow Russia

North Estonia Medical Centre Tallinn Estonia

Service de Dermatologie et Cancérologie Cutanée Hopital de la Timone Marseille France

UniversitätsSpital Zürich Skin Cancer Center University Hospital Zürich Switzerland

University Clinic of Radiotherapy and Oncology Skopje Former Yugoslav Republic of Macedonia

University Hospital Center Sestre Milosrdnice Zagreb Croatia

University Hospital Mother Theresa Tirana Albania

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030986
003      
CZ-PrNML
005      
20171025115416.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2017.01.012 $2 doi
035    __
$a (PubMed)28264791
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kandolf Sekulovic, L $u Department of Dermatology, Medical Faculty, Military Medical Academy, Belgrade, Serbia.
245    10
$a More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments / $c L. Kandolf Sekulovic, K. Peris, A. Hauschild, A. Stratigos, JJ. Grob, P. Nathan, R. Dummer, AM. Forsea, C. Hoeller, H. Gogas, L. Demidov, C. Lebbe, C. Blank, J. Olah, L. Bastholt, D. Herceg, B. Neyns, R. Vieira, J. Hansson, P. Rutkowski, I. Krajsova, M. Bylaite-Bucinskiene, I. Zalaudek, J. Maric-Brozic, N. Babovic, M. Banjin, K. Putnik, G. Weinlich, V. Todorovic, K. Kirov, J. Ocvirk, A. Zhukavets, M. Kukushkina, L. De La Cruz Merino, A. Ymeri, M. Risteski, C. Garbe,
520    9_
$a BACKGROUND: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). MATERIALS AND METHODS: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. RESULTS: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. CONCLUSIONS: Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry.
650    _2
$a akrylonitril $x analogy a deriváty $x ekonomika $x zásobování a distribuce $7 D000181
650    _2
$a aniliny $x ekonomika $x zásobování a distribuce $7 D000814
650    _2
$a humanizované monoklonální protilátky $x ekonomika $x terapeutické užití $7 D061067
650    _2
$a Evropa $x epidemiologie $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dostupnost zdravotnických služeb $x ekonomika $x statistika a číselné údaje $7 D006297
650    _2
$a disparity zdravotní péče $x ekonomika $x statistika a číselné údaje $7 D054625
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x ekonomika $x statistika a číselné údaje $7 D007167
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x ekonomika $x epidemiologie $x terapie $7 D008545
650    _2
$a antigeny CD279 $x antagonisté a inhibitory $7 D061026
650    _2
$a protoonkogenní proteiny B-raf $x antagonisté a inhibitory $7 D048493
650    _2
$a dávkové mechanismy $x statistika a číselné údaje $7 D012051
650    _2
$a nádory kůže $x ekonomika $x epidemiologie $x terapie $7 D012878
650    _2
$a experimentální terapie $x ekonomika $x statistika a číselné údaje $7 D035703
655    _2
$a časopisecké články $7 D016428
700    1_
$a Peris, K $u Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
700    1_
$a Hauschild, A $u Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
700    1_
$a Stratigos, A $u National and Kapodistrian University of Athens, Greece.
700    1_
$a Grob, J-J $u Service de Dermatologie et Cancérologie Cutanée, Hopital de la Timone, Marseille, France.
700    1_
$a Nathan, P $u Mount Vernon Cancer Centre, Northwood, United Kingdom.
700    1_
$a Dummer, R $u UniversitätsSpital Zürich-Skin Cancer Center, University Hospital, Zürich, Switzerland.
700    1_
$a Forsea, A-M $u Carol Davila University of Medicine and Pharmacy, Elias University Hospital Bucharest, Romania.
700    1_
$a Hoeller, C $u Department of Dermatology, Medical University of Vienna, Vienna, Austria.
700    1_
$a Gogas, H $u National and Kapodistrian University of Athens, Greece.
700    1_
$a Demidov, L $u NN Blokhin Russian Cancer Research Center, Moscow, Russia.
700    1_
$a Lebbe, C $u APHP Hospital Saint Louis, Paris, France.
700    1_
$a Blank, C $u Netherland Cancer Institute, Amsterdam, Netherlands.
700    1_
$a Olah, J $u Department of Dermatology and Allergology, University of Szeged, Hungary.
700    1_
$a Bastholt, L $u Department of Oncology, Odense University Hospital, Denmark.
700    1_
$a Herceg, D $u Department of Oncology, University Hospital Zagreb, Croatia.
700    1_
$a Neyns, B $u Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
700    1_
$a Vieira, R $u Department of Dermatology, Medical Faculty, University of Coimbra, Portugal.
700    1_
$a Hansson, J $u Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden.
700    1_
$a Rutkowski, P $u Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland.
700    1_
$a Krajsova, I $u General Teaching Hospital, Prague, Czech Republic.
700    1_
$a Bylaite-Bucinskiene, M $u Department of Dermatology, Vilnius University, Lithuania.
700    1_
$a Zalaudek, I $u Division of Dermatology and Venerology, Medical University of Graz, Graz, Austria.
700    1_
$a Maric-Brozic, J $u University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
700    1_
$a Babovic, N $u Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
700    1_
$a Banjin, M $u Department of Oncology, University Hospital Sarajevo, Bosnia and Herzegovina.
700    1_
$a Putnik, K $u North Estonia Medical Centre, Tallinn, Estonia.
700    1_
$a Weinlich, G $u Department of Dermatology & Venerology & Allergy, Medical University Innsbruck, Austria.
700    1_
$a Todorovic, V $u Clinic for Oncology and Radiotherapy, Podgorica, Montenegro.
700    1_
$a Kirov, K $u Clinic of Oncodermatology, National Cancer Center, Sofia, Bulgaria.
700    1_
$a Ocvirk, J $u Institute of Oncology Ljubljana, Ljubljana, Slovenia.
700    1_
$a Zhukavets, A $u N.N. Alexandrov National Cancer Сenter of Belarus (NCCB), Minsk, Belarus.
700    1_
$a Kukushkina, M $u National Cancer Institute, Kiev, Ukraine.
700    1_
$a De La Cruz Merino, L $u Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
700    1_
$a Ymeri, A $u University Hospital Mother Theresa, Tirana, Albania.
700    1_
$a Risteski, M $u University Clinic of Radiotherapy and Oncology, Skopje, Former Yugoslav Republic of Macedonia.
700    1_
$a Garbe, C $u Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England 1990) $x 1879-0852 $g Roč. 75, č. - (2017), s. 313-322
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28264791 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025115458 $b ABA008
999    __
$a ok $b bmc $g 1254579 $s 992013
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 75 $c - $d 313-322 $e 20170304 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options